Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer

详细信息    查看全文

• 作者：Robert Dreicer
• 关键词：Prostate cancer ; Chemotherapy
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2008
• 出版时间：July-August 2008
• 年：2008
• 卷：26
• 期：4
• 页码：426-429
• 全文大小：83 K

文摘

Despite efforts at early detection with prostate specific antigen-based screening, more than 25,000 patients in the United States will die this year of metastatic prostate cancer. As a consequence both of screening and increased use of androgen deprivation therapy, patients commonly present with low volume, asymptomatic, metastatic disease. Over the past 2 decades chemotherapy for advanced prostate cancer has evolved from a frightful, toxic experience to one that frequently provides clinically meaningful palliation and a modest, but real survival benefit. With the establishment of docetaxel-based chemotherapy as initial therapy, efforts are underway to evaluate the role of second-line systemic therapy options.